By integrating metabolomic, transcriptomic, and epigenomic data, we identified metabolic alterations, especially cysteine-associated pathways, accompanied with the epigenetic changes during the development of primary trastuzumab resistance of HER2-positive breast cancer (Figure 1A). The gene discussed is ERBB2; the disease is breast cancer.